journal article·2025-08-19

Synergizing Ferroptosis Suppressor Protein 1 Gene Silencing and Photodynamic Therapy Based on Photosensitive Lipid Nanoparticles for Colon Cancer Immunotherapy

Jinzhao Liu, Meicen Wu, Chang Yang, Yang Zhou, Xinran Qi, Kang Chen, Xiaoping Zhang, Ni Fan, Changyou Zhan, Weiping Wang

ACS Nano· Volume 19· Issue 32
Publisher page

Abstract

Metastasis and immune escape play crucial roles in the progression of colon cancer. Current chemotherapy and immunotherapy treatments have limited effectiveness in reversing the immunologically cold microenvironment. Therefore, it is essential to investigate efficient strategies to enhance the antitumor immunity. In this study, ferroptosis suppressor protein 1 (FSP1) siRNA and photosensitizer Verteporfin were incorporated into the lipid nanoparticle (LNP) formulation for synergistic colon cancer immunotherapy. We first screened the photosensitive LNP formulations using different types of light-responsive small molecules. The selected photosensitive LNPs were further optimized by modulating surface properties to improve cellular uptake and endosomal escape levels in colon cancer cells. Upon light irradiation, the engineered photosensitive LNPs promoted synergistic ferroptosis by FSP1 gene silencing and oxidative stress, thereby causing immunogenic cell death to stimulate dendritic cell maturation and cytotoxic T lymphocyte response. In a bilateral tumor model, photosensitive LNPs exhibited potent antitumor efficacy and robust immunostimulatory effect upon light irradiation, enabling safe and efficient colon cancer treatment. This study demonstrates a synergistic potential between FSP1 gene silencing and photodynamic therapy, expanding the applications of photosensitive LNPs in clinical cancer treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Ferroptosis and cancer prognosis · Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Pharmaceutical Biotechnology

The University of Hong Kong

Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine

Dr. Li Dak-Sum Research Centre

Department of Medicine, Li Ka Shing Faculty of Medicine

Department of Pharmacology, School of Basic Medical Sciences & State Key Laboratory of Molecular Engineering of Polymers

Fudan University

Funding

Research Grants Council, University Grants Committee · National Natural Science Foundation of China

References (54)

Show source-provided references
1. 10.1016/S1535-6108(02)00053-310.1016/S1535-6108(02)00053-3 ↗
2. 10.3322/caac.2177210.3322/caac.21772 ↗
3. 10.1038/nature2549210.1038/nature25492 ↗
4. 10.1038/s41575-024-00934-z10.1038/s41575-024-00934-z ↗
5. 10.1016/j.jconrel.2023.09.01410.1016/j.jconrel.2023.09.014 ↗
6. 10.1002/ags3.1263310.1002/ags3.12633 ↗
7. 10.1186/s12951-022-01586-410.1186/s12951-022-01586-4 ↗
8. 10.1038/s41580-020-00324-810.1038/s41580-020-00324-8 ↗
9. 10.1016/j.tcb.2022.11.00310.1016/j.tcb.2022.11.003 ↗
10. 10.1038/s41556-024-01425-810.1038/s41556-024-01425-8 ↗
11. 10.1038/s41586-019-1705-210.1038/s41586-019-1705-2 ↗
12. 10.1038/s41586-019-1707-010.1038/s41586-019-1707-0 ↗
13. 10.1002/med.2193310.1002/med.21933 ↗
14. 10.1038/s41568-022-00459-010.1038/s41568-022-00459-0 ↗
15. 10.1016/j.molmed.2023.05.01310.1016/j.molmed.2023.05.013 ↗
16. 10.1038/s41392-020-00428-910.1038/s41392-020-00428-9 ↗
17. 10.1016/j.biomaterials.2022.12168710.1016/j.biomaterials.2022.121687 ↗
18. 10.1002/adhm.20230099410.1002/adhm.202300994 ↗
19. 10.1016/j.ccr.2024.21623610.1016/j.ccr.2024.216236 ↗
20. 10.1021/acsnano.2c1093610.1021/acsnano.2c10936 ↗
21. 10.1039/D5CS00125K10.1039/D5CS00125K ↗
22. 10.1038/s41571-020-0410-210.1038/s41571-020-0410-2 ↗
23. 10.1021/acsabm.4c0031610.1021/acsabm.4c00316 ↗
24. 10.1002/med.2207210.1002/med.22072 ↗
25. 10.3390/ijms24151220410.3390/ijms241512204 ↗
26. 10.1177/1553350622108354510.1177/15533506221083545 ↗
27. 10.1002/smll.20230570810.1002/smll.202305708 ↗
28. 10.1021/acsnano.4c1102410.1021/acsnano.4c11024 ↗
29. 10.1016/j.nantod.2023.10189010.1016/j.nantod.2023.101890 ↗
30. 10.1002/adhm.20240235710.1002/adhm.202402357 ↗
31. 10.1002/advs.20230287210.1002/advs.202302872 ↗
32. 10.1021/acsabm.2c0089110.1021/acsabm.2c00891 ↗
33. 10.1038/s41578-022-00529-710.1038/s41578-022-00529-7 ↗
34. 10.1038/s41573-024-00977-610.1038/s41573-024-00977-6 ↗
35. 10.1016/j.jconrel.2024.04.02210.1016/j.jconrel.2024.04.022 ↗
36. 10.1016/j.bioactmat.2021.10.01810.1016/j.bioactmat.2021.10.018 ↗
37. 10.1016/j.addr.2022.11441610.1016/j.addr.2022.114416 ↗
38. 10.1002/adma.20230530010.1002/adma.202305300 ↗
39. 10.1002/btm2.1021310.1002/btm2.10213 ↗
40. 10.1002/adma.20230326610.1002/adma.202303266 ↗
41. 10.1038/s41392-024-02088-510.1038/s41392-024-02088-5 ↗
42. 10.1016/j.actbio.2022.07.05510.1016/j.actbio.2022.07.055 ↗
43. 10.1007/s12033-023-00891-z10.1007/s12033-023-00891-z ↗
44. 10.1038/s41580-024-00703-510.1038/s41580-024-00703-5 ↗
45. 10.1021/acsnano.1c0049810.1021/acsnano.1c00498 ↗
46. 10.1016/j.tcb.2023.05.00310.1016/j.tcb.2023.05.003 ↗
47. 10.1038/s41419-024-07244-x10.1038/s41419-024-07244-x ↗
48. 10.1016/j.devcel.2025.02.00410.1016/j.devcel.2025.02.004 ↗
49. 10.1007/s10495-024-01966-110.1007/s10495-024-01966-1 ↗
50. 10.7150/thno.11247510.7150/thno.112475 ↗
51. 10.1016/j.immuni.2024.03.01410.1016/j.immuni.2024.03.014 ↗
52. 10.1002/adma.20230326110.1002/adma.202303261 ↗
53. 10.1038/s41577-024-01027-310.1038/s41577-024-01027-3 ↗
54. 10.1007/s13238-020-00707-910.1007/s13238-020-00707-9 ↗